Activity of cabozantinib (XL184) in hepatocellular carcinoma: Results from a phase II randomized discontinuation trial (RDT).
Chris Verslype
Research Funding - Exelixis
Allen Lee Cohn
Research Funding - Exelixis
Robin Katie Kelley
Research Funding - Exelixis
Tsai-Shen Yang
Research Funding - Exelixis
Wu-Chou Su
Research Funding - Exelixis
David A. Ramies
Employment or Leadership Position - Exelixis
Stock Ownership - Exelixis
Yihua Lee
Employment or Leadership Position - Exelixis
Stock Ownership - Exelixis
Xiaodong Shen
Employment or Leadership Position - Exelixis
Stock Ownership - Exelixis
Eric Van Cutsem
Research Funding - Exelixis